NUAK1 promotes organ fibrosis via YAP and TGF-β/SMAD signaling.

Sci Transl Med

Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute, St. Michael's Hospital (Unity Health Toronto) and Department of Medicine, University of Toronto, Toronto, Ontario M5B 1T8, Canada.

Published: March 2022

Fibrosis is a central pathway that drives progression of multiple chronic diseases, yet few safe and effective clinical antifibrotic therapies exist. In most fibrotic disorders, transforming growth factor-β (TGF-β)-driven scarring is an important pathologic feature and a key contributor to disease progression. Yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ) are two closely related transcription cofactors that are important for coordinating fibrogenesis after organ injury, but how they are activated in response to tissue injury has, so far, remained unclear. Here, we describe NUAK family kinase 1 (NUAK1) as a TGF-β-inducible profibrotic kinase that is up-regulated in multiple fibrotic organs in mice and humans. Mechanistically, we show that TGF-β induces a rapid increase in NUAK1 in fibroblasts. NUAK1, in turn, can promote profibrotic YAP and TGF-β/SMAD signaling, ultimately leading to organ scarring. Moreover, activated YAP and TAZ can induce further NUAK1 expression, creating a profibrotic positive feedback loop that enables persistent fibrosis. Using mouse models of kidney, lung, and liver fibrosis, we demonstrate that this fibrogenic signaling loop can be interrupted via fibroblast-specific loss of NUAK1 expression, leading to marked attenuation of fibrosis. Pharmacologic NUAK1 inhibition also reduced scarring, either when initiated immediately after injury or when initiated after fibrosis was already established. Together, our data suggest that NUAK1 plays a critical, previously unrecognized role in fibrogenesis and represents an attractive target for strategies that aim to slow fibrotic disease progression.

Download full-text PDF

Source
http://dx.doi.org/10.1126/scitranslmed.aaz4028DOI Listing

Publication Analysis

Top Keywords

nuak1
8
yap tgf-β/smad
8
tgf-β/smad signaling
8
disease progression
8
nuak1 expression
8
fibrosis
6
nuak1 promotes
4
promotes organ
4
organ fibrosis
4
yap
4

Similar Publications

Targeting the mevalonate pathway potentiates NUAK1 inhibition-induced immunogenic cell death and antitumor immunity.

Cell Rep Med

January 2025

Renji-Med-X Clinical Stem Cell Research Center, Renji Hospital, School of Medicine and School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai 200127, China; Med-X Research Institute, Shanghai Jiao Tong University, Shanghai 200030, China. Electronic address:

The induction of immunogenic cell death (ICD) impedes tumor progression via both tumor cell-intrinsic and -extrinsic mechanisms, representing a robust therapeutic strategy. However, ICD-targeted therapy remains to be explored and optimized. Through kinome-wide CRISPR-Cas9 screen, NUAK family SNF1-like kinase 1 (NUAK1) is identified as a potential target.

View Article and Find Full Text PDF

Background: Stomach adenocarcinoma (STAD) represents a significant global health burden, accounting for a considerable proportion of cancer-related mortalities, and NUAK1, a protein kinase, plays a crucial role in cellular metabolism, cell cycle regulation, migration, and tumor progression. However, its relationship with prognosis and immune infiltration in STAD has not been thoroughly investigated.

Methods: RNA sequencing data from the Cancer Genome Atlas (TCGA) and Genotypic Tissue Expression Project (GTEx) databases were employed to assess disparities in NUAK1 expression between STAD tumour and normal tissues.

View Article and Find Full Text PDF

Nuak1 (NUAK family SnF1-like kinase-1) is a serine-threonine kinase and a member of the AMPK family. Interest in Nuak1 has increased over the years due to the role it plays in several biological processes, from tumor cell invasion and proliferation to Tau stabilization. Nuak1 is expressed in many cancer cell lines and many reports describe this target as an oncogene, the inhibition of which is hypothesized to be valuable for treating various cancer types including glioma.

View Article and Find Full Text PDF

NUAKs promote mTOR/c-Myc-induced glucose and glutamine reprogramming for cell growth and metastasis in breast cancer cells.

Biochim Biophys Acta Mol Basis Dis

January 2025

Cell Signaling and Cancer Biology Laboratory, Department of Biochemistry, Guindy Campus, University of Madras, Chennai 600025, India. Electronic address:

Article Synopsis
  • Breast cancer progression is associated with changes in glucose and glutamine metabolism, with increased expression of NUAK1 and NUAK2 observed in cancer tissues correlating with poor patient prognosis.
  • NUAKs enhance metabolic reprogramming, especially in triple negative breast cancer, by activating mTOR signaling and upregulating the c-Myc transcription factor, leading to increased glucose and glutamine usage for rapid cell proliferation.
  • Targeting NUAKs presents a potential therapeutic strategy to hinder metabolic reprogramming and tumor growth in breast cancer.
View Article and Find Full Text PDF
Article Synopsis
  • The study focuses on abdominal aortic aneurysm (AAA), a condition where the aorta weakens and dilates in the abdomen, aiming to understand the specific cellular mechanisms involved by analyzing proteins in vascular smooth muscle cells (VSMC) from AAA patients versus healthy donors.
  • Using advanced proteomic techniques, researchers found significant differences in proteins linked to extracellular matrix remodeling, energy metabolism, and muscle contractility between AAA patients and healthy individuals.
  • The research revealed changes in phosphorylation patterns affecting structural proteins like those involved in the actin cytoskeleton and signaling pathways, suggesting specific kinases like NUAK1 and MAPK7 may play crucial roles in AAA development.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!